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to explain the rise in Cr and ≥10% rise in serum cystatin levels from
baseline at 24 h. Cr will be assessed at baseline and at 24, 48 and
72 h and CyC will be measured at baseline and at 24 h.
Results: After 48 hrs of CM exposure, Cr increase ≥0.5 mg/dL
occurred in 29 patients (11.3%) whereas increase in CyC ≥10% at
24 hrs after CM exposure occurred in 66 patients (26.08%). The
difference in mean Cr and baseline, 24 hrs and 48 hrs after CM
exposure was not statistically signiﬁcant whereas that between
CyC at baseline and 24 h after CM exposure was signiﬁcant. CyC
detected CIN 24 hrs earlier as compared to Cr. Similarly the dif-
ference between GFR calculated by Cr equation was not statisti-
cally signiﬁcant between pre and post CM exposure but the
difference was signiﬁcant when GFR was calculated using the
combined equation. The risk of CIN was higher in patients with
pre-existing CKD, diabetes, advanced age, haemodynamic instabil-
ity, heart failure (LVEF < 40%), patients with ACS and higher con-
trast volumes.
Conclusions: The assessment of CyC at 24 hours after CM exposure
allows an early diagnosis of CIN. Also CyC equation and the
combined equation (Cr + CyC) for measurement of GFR accurately
identiﬁed the patients with CIN even at 24 hrs after CM exposure,
in contrast to Creatinine which took 48-72 hrs. Hence the manage-
ment strategies for CIN can be started earlier by 24-48 hrs when
CyC is used as a marker for CIN which would improve long term
outcomes.
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Background: Pulmonary embolism (PE) is one of themajor cause of
cardiovascular mortality. High index of suspicion is necessary for
diagnosis. PE likelihood scoring is a useful clinical tool for risk
stratiﬁcation and management. This was a prospective registry to
study the clinical features, clinical likelihood scoring, risk strati-
ﬁcation and management of PE.
Methods: Consecutive cases hospitalized over a period of 3 years
were studied. Revised Geneva score was applied to all cases of
suspected pulmonary embolism. Most cases had PE conﬁrmed by
CT pulmonary angiography. Risk stratiﬁcation (Pulmonary Embo-
lism Severity Index from 2015) was used to guide the treatment
strategy.
Results: There were 44 patients of pulmonary embolism, 26 being
male. The mean age for male patients was 43.8 years and for
females 55.4 years. Among 44 patients, 11 (25.0%) patients had
surgery or immobilisation in the past 30 days, 15 (34.09%) patients
had DVT. 4 (9.09%) patients had diabetes, 3 (6.81%) had hyperten-
sion. 6 (13.6%) patients were smokers. 37 (84.0%) patients had
breathlessness. ECG revealed sinus tachycardia in 34 (77.2%). Echo-
cardiogram showed dilated right atrium (RA) & right ventricle (RV)
in 32 (72.7%) patients and RV dysfunction in 10 (22.7%) patients.
The mean modiﬁed Geneva score was 8.18 for males and 9.7 for
female. CT pulmonary angiography was done in 33 patients which
conﬁrmed PE in 32 cases. Risk stratiﬁcation according to expected
pulmonary embolism-related early mortality rate stratiﬁed 11
(25.0%) patients in high risk group, 27 (61.3%) patients in inter-
mediate risk group & 6 (13.6%) patients in low risk group. 27 (61.3%)
patients were thrombolysed with tenecteplase & 3 (6.8%) with
reteplase. 1 patient had emergency surgical thrombo-endartect-
omy, recovering fully after an eventful post-operative period. Post-
treatment most patients showed improvement.
Conclusion: Modiﬁed Geneva score along with imaging investiga-
tions helped in establishing diagnosis. Thrombolytic therapy in
high risk cases and selected intermediate risk cases was safe and
effective.
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Background: It is well proven that sildenaﬁl improves pulmonary
hemodynamics and exercise capacity in patients with primary
pulmonary hypertension. However, the drug armamentarium
for secondary pulmonary hypertension is limited. Sildenaﬁl may
also be helpful in this subgroup. Certain studies have shown
promising results but none of the magnitude to promulgate new
recommendations.
Methods: In this double-blind, placebo-controlled study, we ran-
domly assigned 106 patients with symptomatic secondary PAH
(idiopathic DCMP, heart failure with preserved EF, COPD, and other
lung parenchymal disease, valvular heart disease) to placebo or
sildenaﬁl (53 in each group). Sildenaﬁl was given orally 25 mg TID
for 6 weeks. The primary end point was the change from baseline
to week 6 in the distance walked in 6 minutes. We also assessed
clinical improvement (improvement in 6 minute walk test, and
NYHA functional class, change in Borg dyspnoea index) and
change in hemodynamic parameters (PASP, LVEF).
Results: Of the 106 patients, included secondary PAH was due to
COPD in 21 (19.8%), valvular heart disease in 53 (50%), heart failure
with preserved EF in 16 (15%), idiopathic DCMP in 11 (10.2%) and
other lung parenchymal diseases in 5 (5%). The mean increase in
the distance walked after 6 weeks of therapy was 54 min sildenaﬁl
group and 13 m in placebo group p = 0.04. In the sildenaﬁl group
signiﬁcantly greater number of patients improved by at least one
functional class (23% vs 11%, p = 0.003). The mean NYHA class at 6
weeks was 2.0  0.2 in the sildenaﬁl group versus 2.8  0.4 in the
placebo group, p = 0.02. The mean PASP signiﬁcantly decreased in
the sildenaﬁl group at 6 weeks (48  6 mmHg), compared to pla-
cebo (58  6 mmHg), p = 0.02. LVEF was higher in the sildenaﬁl
group, 60  10% versus 55  10% in the placebo group, but did
not reach statistically signiﬁcant difference.
Conclusion: Sildenaﬁl improves exercise capacity, functional class,
and hemodynamics in patients with PAH. PDE-5 inhibition may
represent an important therapy for patients with secondary PAHif,
the beneﬁts observed in our study are conﬁrmed in larger clinical
trials.
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Background: Atrial ﬁbrillation increases the risks of stroke and
death. Although warfarin reduces the risks of stroke and death, it
increases the risk of hemorrhage along with its other drawbacks.
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